News | Breast Imaging | March 15, 2023

In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results of the study were published in Radiology, a journal of the Radiological Society of North America (RSNA) 

In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results of the study were published in Radiology, a journal of the Radiological Society of North America (RSNA)

Images in a 42-year-old woman who presented for routine screening. (A) Two-dimensional craniocaudal digital mammogram and (B) two-dimensional mediolateral digital mammogram show heterogeneously dense breast tissue with no abnormality. (C) Mediolateral digital breast tomosynthesis image shows subtle architectural distortion (arrows) extending superiorly from the nipple level. (D) Target US image of the right breast shows a highly suspicious, hypoechoic, irregular mass (arrow). US-guided core biopsy yielded invasive ductal carcinoma with extensive ductal carcinoma in situ (T2N0M0; estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative). (E) Right-breast MRI scan acquired to evaluate the extent of disease shows a clip artifact in the superior aspect of the irregular enhancing mass (arrows). No other suspicious lesions were seen. Image courtesy of RSNA 


March 15, 2023 — In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results of the study were published today, March 14, in Radiology, a journal of the Radiological Society of North America (RSNA). 

Breast cancer is the most common cancer among women in the United States. While breast cancer mortality has been on the decline since the late 1980s due to improvements in early detection and treatment, it still remains the leading cause of cancer death among women. 

The five-year relative survival rate of breast cancer when it is detected early in its localized stage is 99%, according to the American Cancer Society. Regular screening is the most reliable method for the early detection of breast cancer. 

Screening with two-dimensional (2D) digital mammography alone is still the standard of care at many sites, but it has its limitations due to its inability to detect some cancers. There is a growing amount of evidence that DBT, a more advanced technology, has a higher breast cancer detection rate due to its ability to capture multiple X-ray images of the breast from different angles rather than the typical single image obtained with a standard 2D mammogram. DBT is especially beneficial for women with denser breast tissue. 

“The purpose of our study was to evaluate screening outcomes among a large cohort of women in the United States who were screened with either 2D digital mammography alone or with DBT,” said study co-author Emily F. Conant, M.D., FSBI, professor of radiology and chief in the Division of Breast Imaging at the Hospital at the University of Pennsylvania in Philadelphia. 

For this retrospective cohort study, Dr. Conant and colleagues compiled data from five large health care systems across the United States. The study group consisted of over 1 million women aged 40 to 79 who were screened with either DBT or 2D digital mammography alone between January 2014 and December 2020. The screening outcomes such as cancer detection and false positive rates were compared across the two screening groups. 

“This study was extremely large with most women having at least 2 screens resulting in over 2 million screening exams across five large and diverse health care systems,” Dr. Conant said. 

Compared to 2D digital mammography alone, DBT was associated with important improvements in screening outcomes. The cancer detection rate for patients screened with DBT was higher at 5.3 per 1,000 screened, compared to 4.5 per 1,000 screened with 2D digital mammography only. DBT also had a lower rate of false positives and recalls from screening. 

“We showed that the most important mammographic screening outcomes, increased cancer detection combined with fewer false positives, were significantly improved when women were screened with digital breast tomosynthesis compared to 2D digital mammography alone,” Dr. Conant said. “Therefore, women should seek out sites that routinely offer breast cancer screening with DBT.” 

For more information: www.rsna.org 

 

Related Breast Density Content: 

Creating Patient Equity: A Breast Density Legislative Update 

FDA Needs to Ensure that Information on Dense Breast Notifications are Clear and Understandable to all Members of the Public 

AI Provides Accurate Breast Density Classification 

VIDEO: The Impact of Breast Density Technology and Legislation 

VIDEO: Personalized Breast Screening and Breast Density 

VIDEO: Breast Cancer Awareness - Highlights of the NCoBC 2016 Conference 

Fake News: Having Dense Breast Tissue is No Big Deal 

The Manic World of Social Media and Breast Cancer: Gratitude and Grief 

  

Related Breast Imaging Content: 

Single vs. Multiple Architectural Distortion on Digital Breast Tomosynthesis 

Today's Mammography Advancements  

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings  

AI DBT Impact on Mammography Post-breast Therapy  

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI  

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs  

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography 

Study Finds Racial Disparities in Access to New Mammography Technology 

American College of Radiology (ACR) Launches Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in Collaboration With GE Healthcare and the Breast Cancer Research Foundation 


Related Content

News | Lung Imaging

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...

Time November 07, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 4, 2025 — Altamont Software, a provider of enterprise medical connectivity solutions, has announced the ...

Time November 05, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
News | RSNA 2025

Oct. 31, 2025 — Echolight plans to demonstrate its bone density scanning technology at the Radiological Society of North ...

Time November 03, 2025
arrow
News | Breast Imaging

Oct. 28, 2025 — QT Imaging Holdings, Inc., a medical device company focused on radiation-free imaging technology, has ...

Time October 28, 2025
arrow
Feature | Breast Imaging

Despite decades of progress in breast imaging, one challenge continues to test even the most skilled radiologists ...

Time October 24, 2025
arrow
News | Breast Imaging

Oct. 15, 2025 — Leading into Breast Cancer Awareness Month, Fujifilm Healthcare Americas Corp. and Beekley Medical ...

Time October 15, 2025
arrow
News | RSNA 2025

Oct. 7, 2025 — RSNA Ventures, a mission-aligned subsidiary of Radiological Society of North America (RSNA), has ...

Time October 08, 2025
arrow
News | RSNA 2025

Oct. 7, 2025 – Clairity Inc., a leader in AI-based breast cancer risk prediction, will make five scientific ...

Time October 07, 2025
arrow
Subscribe Now